Skip to Main Content


What people with cancer should know:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Here you can browse the complete list of publications for studies listed on CDAS.

Publication Year
Title PubMed Id Authors Journal Abbreviation Year Studies
Do cancer survivors develop healthier lifestyle behaviors than the cancer-free population in the PLCO study? 27837443 Hawkins ML, Buys SS, Gren LH, Simonsen SE, Kirchhoff AC, Hashibe M J Cancer Surviv 2017 PLCO
Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men. 27480499 Stone BV, Shoag J, Halpern JA, Mittal S, Lewicki P, Golombos DM, Bedretdinova D, Chughtai B, Barbieri CE, Lee RK BJU Int. 2017 PLCO
Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. 27911486 Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL Cancer 2017 PLCO
Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer. 27699819 Shoaibi A, Rao GA, Cai B, Rawl J, Haddock KS, Hébert JR Prostate 2017 PLCO
Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm. 27569432 Halpern JA, Shoag JE, Mittal S, Oromendia C, Ballman KV, Hershman DL, Wright JD, Shih YT, Nguyen PL, Hu JC J. Urol. 2017 PLCO
Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. 27770434 Trabert B, Eldridge RC, Pfeiffer RM, Shiels MS, Kemp TJ, Guillemette C, Hartge P, Sherman ME, Brinton LA, Black A, Chaturvedi AK, Hildesheim A, Berndt SI, Safaeian M, Pinto L, Wentzensen N Int. J. Cancer 2017 PLCO
Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial. 27754927 Kelly SP, Graubard BI, Andreotti G, Younes N, Cleary SD, Cook MB J. Natl. Cancer Inst. 2017 PLCO
Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. 28510291 Wang Y, Freedman JA, Liu H, Moorman PG, Hyslop T, George DJ, Lee NH, Patierno SR, Wei Q Int. J. Cancer 2017 PLCO
Circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO cancer screening trial. 28484923 Liao LM, Hofmann JN, Cho E, Pollak MN, Chow WH, Purdue MP Cancer Causes Control 2017 PLCO
Do aspirin and other NSAIDs confer a survival benefit in men diagnosed with prostate cancer? A pooled analysis of NIH-AARP and PLCO cohorts. 28507039 Zhou CK, Daugherty SE, Liao LM, Freedman ND, Abnet CC, Pfeiffer R, Cook MB Cancer Prev Res (Phila) 2017 PLCO
Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules. 28694742 Birse CE, Tomic JL, Pass HI, Rom WN, Lagier RJ Clin Proteomics 2017 PLCO
Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. 29114854 Reger MK, Zollinger TW, Liu Z, Jones JF, Zhang J Int. J. Cancer 2017 PLCO
Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. 28376197 Kreimer AR, Johansson M, Yanik EL, Katki HA, Check DP, Lang Kuhs KA, Willhauck-Fleckenstein M, Holzinger D, Hildesheim A, Pfeiffer R, Williams C, Freedman ND, Huang WY, Purdue MP, Michel A, Pawlita M, Brennan P, Waterboer T J. Natl. Cancer Inst. 2017 PLCO
Prospective study of DNA methylation at chromosome 8q24 in peripheral blood and prostate cancer risk. 28463958 Barry KH, Moore LE, Sampson JN, Koutros S, Yan L, Meyer A, Reddy M, Oler AJ, Cook MB, Fraumeni JF, Yeager M, Amundadottir LT, Berndt SI Br. J. Cancer 2017 PLCO
Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. 28702814 Han SS, Erdogan SA, Toumazis I, Leung A, Plevritis SK Cancer Causes Control 2017 PLCO
Vasectomy and Risk of Prostate Cancer in a Screening Trial. 28830873 Shoag J, Savenkov O, Christos PJ, Mittal S, Halpern JA, Askin G, Shoag D, Golan R, Lee DJ, O'Malley P, Najari B, Eisner B, Hu JC, Scherr D, Schlegel P, Barbieri CE Cancer Epidemiol. Biomarkers Prev. 2017 PLCO
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. 28869989 Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R Ann. Intern. Med. 2017 PLCO
Early detection versus primary prevention in the PLCO flexible sigmoidoscopy screening trial: Which has the greatest impact on mortality? 28976536 Doroudi M, Schoen RE, Pinsky PF Cancer 2017 PLCO
Utility of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer. 29061540 Halpern JA, Oromendia C, Shoag JE, Mittal S, Cosiano MF, Ballman KV, Vickers AJ, Hu JC J. Urol. 2017 PLCO
Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival. 29156299 Temkin SM, Miller EA, Samimi G, Berg CD, Pinsky P, Minasian L Eur. J. Cancer 2017 PLCO